Valuation: FibroBiologics, Inc.

Market Cap 4.73M 4.13M 3.8M 3.54M 6.71M 450M 6.82M 45.59M 17.72M 221M 17.74M 17.36M 762M P/E 2026 *
-0.88x
P/E 2027 * -0.4x
Enterprise Value 4.73M 4.13M 3.8M 3.54M 6.71M 450M 6.82M 45.59M 17.72M 221M 17.74M 17.36M 762M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.40%
1 week+5.98%
Current month-7.62%
1 month-18.18%
3 months-36.56%
6 months-81.75%
Current year-80.54%
1 week 0.78
Extreme 0.7806
0.98
1 month 0.73
Extreme 0.731
1.04
Current year 0.73
Extreme 0.731
9.6
1 year 0.73
Extreme 0.731
14.68
3 years 0.73
Extreme 0.731
1,100
5 years 0.73
Extreme 0.731
1,100
10 years 0.73
Extreme 0.731
1,100
Manager TitleAgeSince
Chief Executive Officer 62 07/04/2021
Director of Finance/CFO 53 08/06/2025
Chief Tech/Sci/R&D Officer 57 31/07/2021
Director TitleAgeSince
Director/Board Member 60 07/04/2021
Chairman 62 07/04/2021
Director/Board Member 51 07/04/2021
Date Insider Type Main position Quantity % Market Cap.
06-22Free

Director

30,803 0.5914%
06-22Free

Director

30,803 0.5914%
06-22Free

Director

30,803 0.5914%
Change 5-day change 1-year change 3-year change Capi.($)
-3.40%+5.98%-92.85% - 4.73M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.24%+9.65%+39.53%+147.40% 24.55B
Weighted average by Cap. +2.46%+6.47%+58.32%+136.98%

Financials

2026 *2027 *
Net sales - -
Net income -20.36M -17.8M -16.35M -15.24M -28.91M -1.94B -29.35M -196M -76.33M -953M -76.41M -74.77M -3.28B -24.01M -20.99M -19.29M -17.98M -34.11M -2.29B -34.62M -232M -90.03M -1.12B -90.13M -88.2M -3.87B
Net Debt - -
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Employees
15
Date Price Change Volume
02/07/26 US$0.8755 -3.40% 59,071
01/07/26 US$0.9063 -4.37% 106,928
30/06/26 US$0.9477 +19.22% 268,908
29/06/26 US$0.7949 -3.78% 230,979
26/06/26 US$0.8261 +12.67% 1,098,768
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8755USD
Average target price
13.50USD
Spread / Average Target
+1,441.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBLG Stock